Xeljanz and Other JAK Inhibitors: Drug Safety Concerns Indicated by Recent FDA Actions

April 15, 2021

Belviq Recall Aftermath: Further FDA Action in 2021 Means There Will Be No Generic Belviq Products

April 7, 2021

Possible Ramifications of Recent FDA Alert About Xeljanz Heart Problems and Xeljanz-related Cancers

March 23, 2021

Elmiron Drug Safety-related Labeling Changes for Pigmentary Maculopathy Side Effect

March 16, 2021

Beovu Vision Loss Lawsuits Involve Serious Eye Problems due to Beovu Injections Reactions

March 10, 2021

Past Elmiron Use Linked to Pigmentary Maculopathy and Vision Loss, Again, by Two Recent Medical Studies

February 24, 2021

Xeljanz Has A New Drug Safety Issue, We Just Don't Know How Significant It Is, Yet

February 17, 2021

Xeljanz FDA Drug Safety Communication in February 2021 Puts Heightened Scrutiny on Pfizer

February 11, 2021

Beovu Side Effects Have Caused Eye Doctors to Avoid Beovu and Use Other Safer AMD Drugs Instead

January 29, 2021

Elmiron Maculopathy Secondary to Pentosan Polysulfate (PPS) Toxicity: Medical Journal Article

January 25, 2021